NCT01180959 2022-11-07
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
3 trialsNCT00881751 2017-09-11
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Medical University of South Carolina
Phase 2 Completed
NCT00605722 2014-07-14
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
Hoffmann-La Roche
Phase 2 Completed